A U.S. judge has ruled in favor of an FTC petition to drop its case against the proposed merger between Illumina (NSDQ:ILMN) and Grail. The Financial Times reported that the ruling — with dropped the case without prejudice — allows the EU to investigate the merger while the deal remains blocked. In April the European Commission’s […]
Illumina Inc.
MedTech 100 roundup: New heights reached again
One week after recording its all-time best performance, the medtech industry again topped itself, storming even further ahead. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has been on the rise since April began, with last week’s mark of 112.25 (April 16) representing an all-time best, topping the […]
EU to look into Illumina’s proposed acquisition of Grail
The European Commission’s Directorate-General for Competition announced today that it will review Illumina’s proposed $8 billion acquisition of Grail. The move, covered in media reports, comes weeks after the companies delayed the deal until after Sept. 20 while the U.S. Federal Trade Commission challenges the deal. Grail is one of several companies competing to develop […]
MedTech 100 roundup: Heading back to previous heights?
Although March brought on tough times for top stocks in the medtech industry, April is already showing signs of a rebound. The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest […]
DTW Podcast: Earnhardt shares how Abbott shifted gears to counter pandemic; Grail still looks to upend oncology
This week, we’ll talk with Abbott’s medical devices EVP Lisa Earnhardt about how the life sciences giant pivoted during the pandemic. Earnhardt shares what programs were given greater priority when the lockdown’s impact became clear and why the company performed so well in one of its key businesses. We also explore this week’s news that […]
Illumina postpones $8B Grail deal amid FTC challenge
Illumina (NSDQ:ILMN) has delayed its proposed $8 billion acquisition of Grail amid a FTC challenge. The companies have agreed to postpone the planned purchase until after Sept. 20 while the FTC challenges the deal, according to a temporary restraining order issued out of U.S. District Court in the District of Columbia. News of Illumina’s agreement […]
Illumina vows to pursue Grail purchase despite FTC challenge
Illumina (NSDQ:ILMN) announced today that it disagrees with and will oppose the FTC’s challenge to its acquisition of Grail. San Diego-based Illumina announced in September that it entered into an agreement to acquire the cancer detection startup that spun out from the company four years ago for cash and stock consideration of $8 billion. Founded […]
Illumina to acquire Grail for $8B, expands cancer early detection
Illumina (NSDQ:ILMN) announced today that it entered into an agreement to acquire Grail for cash and stock consideration of $8 billion. Last week, it was reported that Illumina was looking to purchase the cancer detection startup that spun out from the company four years ago and the companies confirmed that to be true today. Grail was […]
Illumina may buy back Grail
Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup. That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter. Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct […]
NIH to boost COVID-19 testing capabilities
The National Institutes of Health announced a $129.3 million plan to support scaling and manufacturing for COVID-19 tests. As part of its Rapid Acceleration of Diagnostics (RADx) initiative, NIH is awarding contracts to nine companies for their technologies that include portable point-of-care tests for immediate results and high-throughput laboratories that can produce results in 24 […]
Illumina gains FDA EUA for sequencing-based COVID-19 test
Illumina (NSDQ:ILMN) announced that it received FDA emergency use authorization (EUA) for its COVIDSeq sequencing-based COVID-19 diagnostic test. COVIDSeq uses upper respiratory specimens, such as a nasopharyngeal or oropharyngeal swab, and delivers sample receipt to result in 24 hours with the NovaSeq 6000 sequencing system, according to a news release. Illumina’s high-throughput, in vitro diagnostic test […]